Puma VCT 13 PLC
24 July 2026
Puma VCT 13
Offer for Subscription - Update
On 24 September 2025 Puma VCT 13 plc (the "Company") published a prospectus in relation to an offer for subscription for new ordinary shares of £0.0005 each in the Company to raise up to £50 million, with an over-allotment facility to raise up to a further £20 million which has been exercised (the "Offer").
Having raised gross proceeds of more than £53.5 million as of 23 July 2026, the Company announces that the Offer will be closed to further applications at 5.00 pm on 25 August 2026 with the final allotment expected to take place on or around 28 August 2026 and admission expected to take place within two business days of such allotment. The closing date may be brought forward at the Directors' discretion by way of an announcement.
For further information please contact:
Eliot Kaye
Puma VCT 13 plc
020 7408 4050
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.